MCID: TBR024
MIFTS: 45

Tuberous Sclerosis-1 malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Eye diseases, Cardiovascular diseases, Nephrological diseases, Skin diseases, Fetal diseases

Aliases & Classifications for Tuberous Sclerosis-1

About this section
Sources:
49OMIM, 11diseasecard, 51Orphanet, 67UniProtKB/Swiss-Prot, 65UMLS, 22GeneTests, 23Genetics Home Reference, 21GeneReviews, 45NIH Rare Diseases, 24GTR, 28ICD10 via Orphanet, 37MESH via Orphanet, 66UMLS via Orphanet, 34MedGen, 36MeSH, 61The Human Phenotype Ontology
See all MalaCards sources

Aliases & Descriptions for Tuberous Sclerosis-1:

Name: Tuberous Sclerosis-1 49 11
Tuberous Sclerosis Complex 21 22 23 51 67
Bourneville Disease 21 22 23
Tuberous Sclerosis 51 67 65
Tuberous Sclerosis, Type 1 45 24
Bourneville Syndrome 51 67
Tuberous Sclerosis 1 67 65
Epiloia 22 23
Bourneville Pringle Syndrome 22
 
Bourneville Phakomatosis 23
Bourneville's Disease 22
Sclerosis Tuberosa 23
Cerebral Sclerosis 23
Tuberose Sclerosis 23
Phakomatosis Ts 22
Tsc1 67
Ts 67

Characteristics:

Orphanet epidemiological data:

51
tuberous sclerosis complex:
Inheritance: Autosomal dominant; Prevalence: 1-9/1000000 (United States),1-5/10000 (Europe),1-9/100000 (Europe),1-9/100000 (United Kingdom),1-9/100000 (Taiwan, Province of China); Age of onset: Childhood

HPO:

61
tuberous sclerosis-1:
Onset and clinical course: phenotypic variability
Inheritance: autosomal dominant inheritance


Classifications:



External Ids:

OMIM49 191100
Orphanet51 805
ICD10 via Orphanet28 Q85.1
MESH via Orphanet37 D014402
UMLS via Orphanet66 C0041341
MeSH36 D014402
UMLS65 C1854465

Summaries for Tuberous Sclerosis-1

About this section
OMIM:49 Tuberous sclerosis complex (TSC) is an autosomal dominant multisystem disorder characterized by hamartomas in multiple... (191100) more...

MalaCards based summary: Tuberous Sclerosis-1, also known as tuberous sclerosis complex, is related to tuberous sclerosis and polycystic kidney disease, infantile severe, with tuberous sclerosis, and has symptoms including prominent occiput, eeg abnormality and neoplasm of the nervous system. An important gene associated with Tuberous Sclerosis-1 is TSC1 (Tuberous Sclerosis 1), and among its related pathways are and Akt Signaling Pathway. Affiliated tissues include skin, kidney and brain.

Genetics Home Reference:23 Tuberous sclerosis complex is a genetic disorder characterized by the growth of numerous noncancerous (benign) tumors in many parts of the body. These tumors can occur in the skin, brain, kidneys, and other organs, in some cases leading to significant health problems. Tuberous sclerosis complex also causes developmental problems, and the signs and symptoms of the condition vary from person to person.

UniProtKB/Swiss-Prot:67 Tuberous sclerosis 1: An autosomal dominant multi-system disorder that affects especially the brain, kidneys, heart, and skin. It is characterized by hamartomas (benign overgrowths predominantly of a cell or tissue type that occurs normally in the organ) and hamartias (developmental abnormalities of tissue combination). Clinical manifestations include epilepsy, learning difficulties, behavioral problems, and skin lesions. Seizures can be intractable and premature death can occur from a variety of disease-associated causes.

GeneReviews summary for NBK1220

Related Diseases for Tuberous Sclerosis-1

About this section

Diseases in the Tuberous Sclerosis family:

tuberous sclerosis-1

Diseases related to Tuberous Sclerosis-1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 35)
idRelated DiseaseScoreTop Affiliating Genes
1tuberous sclerosis13.1
2polycystic kidney disease, infantile severe, with tuberous sclerosis12.6
3autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis12.6
4cerebral sclerosis similar to pelizaeus-merzbacher disease12.3
5adrenoleukodystrophy11.7
6gilles de la tourette syndrome11.6
7turner syndrome11.6
8metachromatic leukodystrophy11.6
9mitochondrial dna depletion syndrome 4a11.5
10balo concentric sclerosis11.5
11timothy syndrome11.4
12tsc2 angiomyolipomas, renal, modifier of10.6
13pulmonary fibrosis10.4
14buschke-ollendorff syndrome10.1TSC1, TSC2
15benign ependymoma10.1TSC1, TSC2
16selective iga deficiency disease10.1TSC1, TSC2
17pilomyxoid astrocytoma10.1TSC1, TSC2
18carcinoma arising in nasal papillomatosis10.1TSC1, TSC2
19collecting duct carcinoma10.1TSC1, TSC2
20gastrointestinal system cancer10.1TSC1, TSC2
21ganglioglioma10.1TSC1, TSC2
22breast benign neoplasm10.1TSC1, TSC2
23corneal fleck dystrophy10.1TSC1, TSC2
24prostatic urethra urothelial carcinoma10.1TSC1, TSC2
25iodine hypothyroidism10.1TSC1, TSC2
26hepatic angiomyolipoma10.0TSC1, TSC2
27focal cortical dysplasia, taylor balloon cell type10.0TSC1, TSC2
28qazi markouizos syndrome10.0TSC1, TSC2
29cerebellar liponeurocytoma10.0TSC1, TSC2
30idiopathic generalized epilepsy9.9TSC1, TSC2
31hereditary retinal dystrophy9.9TSC1, TSC2
32narcolepsy9.9TSC1, TSC2
33paranasal sinus disease9.8CCL26, TSC1, TSC2
34autoimmune hepatitis9.7TSC1, TSC2
35lymphangioleiomyomatosis8.9CCL26, COL5A1, RPL7A, TSC1, TSC2

Graphical network of the top 20 diseases related to Tuberous Sclerosis-1:



Diseases related to tuberous sclerosis-1

Symptoms for Tuberous Sclerosis-1

About this section

Symptoms by clinical synopsis from OMIM:

191100

Clinical features from OMIM:

191100

Symptoms:

 51 (show all 44)
  • prominent occiput/occipital bossing
  • follicular/erythematous/edematous papules/milium
  • cutaneous neurofibromas/facial angiofibromas/koenen tumors
  • adenoma sebaceum
  • pedunculated skin lesions
  • eeg anomalies
  • central nervous system/peripheral nerves neoplasm/tumor/carcinoma/cancer
  • autosomal dominant inheritance
  • retinal hamartoma
  • optic nerve anomaly/optic atrophy/anomaly of the papilla
  • macules
  • irregular/patchy skin hypopigmentation
  • cafe-au-lait spot
  • capillary hemangioma/nevus/naevus flammeus/port-wine stain
  • subcutaneous nodules/lipomas/tumefaction/swelling
  • ungual/paraungual fibromas (fingernails)
  • ungual/parungual fibromas (toenails)
  • seizures/epilepsy/absences/spasms/status epilepticus
  • intellectual deficit/mental/psychomotor retardation/learning disability
  • psychic/behavioural troubles
  • coloboma of iris
  • gingivitis
  • enamel anomaly
  • macrodactyly/fingers hypertrophy/megalodactyly (hand)
  • structural anomalies of the liver and the biliary tract
  • structural anomalies of the pancreas
  • structural anomalies of the respiratory system and diaphragm
  • abnormal pleura/hydrothorax/pleuresia/pleural effusion/chylothorax
  • respiratory distress/dyspnea/respiratory failure/lung volume reduction
  • emphysema
  • visceral angiomatosis (excluding skin)
  • cardiac rhythm disorder/arrhythmia
  • heart/cardiac failure
  • arterial aneurism (excluding aorta)
  • lymphangioma/lymphatic malformations
  • polycystic kidneys
  • renal failure
  • hypothyroidy
  • precocious puberty
  • corpus callosum/septum pellucidum total/partial agenesis
  • intracranial/cerebral calcifications
  • cranial hypertension
  • heart/cardiac tumor
  • kidney/renal neoplasm/tumor/carcinoma/cancer

HPO human phenotypes related to Tuberous Sclerosis-1:

(show all 67)
id Description Frequency HPO Source Accession
1 prominent occiput hallmark (90%) HP:0000269
2 eeg abnormality hallmark (90%) HP:0002353
3 neoplasm of the nervous system hallmark (90%) HP:0004375
4 adenoma sebaceum hallmark (90%) HP:0009720
5 optic atrophy typical (50%) HP:0000648
6 behavioral abnormality typical (50%) HP:0000708
7 cafe-au-lait spot typical (50%) HP:0000957
8 hypermelanotic macule typical (50%) HP:0001034
9 hypopigmented skin patches typical (50%) HP:0001053
10 seizures typical (50%) HP:0001250
11 retinal hamartoma typical (50%) HP:0009594
12 cognitive impairment typical (50%) HP:0100543
13 ungual fibroma typical (50%) HP:0100804
14 intellectual disability 30% HP:0001249
15 renal insufficiency occasional (7.5%) HP:0000083
16 polycystic kidney dysplasia occasional (7.5%) HP:0000113
17 gingivitis occasional (7.5%) HP:0000230
18 iris coloboma occasional (7.5%) HP:0000612
19 abnormality of dental enamel occasional (7.5%) HP:0000682
20 hypothyroidism occasional (7.5%) HP:0000821
21 precocious puberty occasional (7.5%) HP:0000826
22 abnormality of the liver occasional (7.5%) HP:0001392
23 congestive heart failure occasional (7.5%) HP:0001635
24 abnormality of the pancreas occasional (7.5%) HP:0001732
25 respiratory insufficiency occasional (7.5%) HP:0002093
26 emphysema occasional (7.5%) HP:0002097
27 abnormality of the pleura occasional (7.5%) HP:0002103
28 cerebral calcification occasional (7.5%) HP:0002514
29 increased intracranial pressure occasional (7.5%) HP:0002516
30 aneurysm occasional (7.5%) HP:0002617
31 aplasia/hypoplasia of the corpus callosum occasional (7.5%) HP:0007370
32 renal neoplasm occasional (7.5%) HP:0009726
33 arrhythmia occasional (7.5%) HP:0011675
34 neoplasm of the heart occasional (7.5%) HP:0100544
35 macrodactyly of finger occasional (7.5%) HP:0100746
36 visceral angiomatosis occasional (7.5%) HP:0100761
37 lymphangioma occasional (7.5%) HP:0100764
38 premature chromatid separation HP:0200024
39 infantile spasms HP:0012469
40 chordoma HP:0010762
41 optic glioma HP:0009734
42 cardiac rhabdomyoma HP:0009729
43 achromatic retinal patches HP:0009727
44 subungual fibromas HP:0009724
45 dental enamel pits HP:0009722
46 shagreen patch HP:0009721
47 adenoma sebaceum HP:0009720
48 hypomelanotic macule HP:0009719
49 cortical tubers HP:0009717
50 subependymal nodules HP:0009716
51 astrocytoma HP:0009592
52 projection of scalp hair onto lateral cheek HP:0009554
53 attention deficit hyperactivity disorder HP:0007018
54 renal angiomyolipoma HP:0006772
55 renal cell carcinoma HP:0005584
56 ependymoma HP:0002888
57 cerebral calcification HP:0002514
58 abnormality of the respiratory system HP:0002086
59 wolff-parkinson-white syndrome HP:0001716
60 subcutaneous nodule HP:0001482
61 specific learning disability HP:0001328
62 cafe-au-lait spot HP:0000957
63 precocious puberty HP:0000826
64 hypothyroidism HP:0000821
65 autism HP:0000717
66 gingival fibromatosis HP:0000169
67 renal cyst HP:0000107

Drugs & Therapeutics for Tuberous Sclerosis-1

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)15 Company Approval Date
1
Afinitor 15 41 EVEROLIMUS Novartis March 2009
FDA Label: Afinitor
Disease/s that Drug Treats:renal cell carcinoma/ renal angiomyolipoma associated with tuberous sclerosis complex/ advanced pancreatic neuroendocrine tumors/ hormone receptor-positive, HER2-negative breast cancer
Indications and Usage:15 AFINITOR is a kinase inhibitor indicated for the treatment of: postmenopausal women with advanced hormone receptor-positive, HER2- negative breast cancer (advanced HR+ BC) in combination with exemestane after failure of treatment with letrozole or anastrozole. (1.1) adults with progressive neuroendocrine tumors of pancreatic origin (PNET) that are unresectable, locally advanced or metastatic. AFINITOR is not indicated for the treatment of patients with functional carcinoid tumors. (1.2) adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. (1.3) adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. The effectiveness of AFINITOR in the treatment of renal angiomyolipoma is based on an analysis of durable objective responses in patients treated for a median of 8.3 months. Further follow-up of patients is required to determine long-term outcomes. (1.4) AFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the treatment of: pediatric and adult patients with tuberous sclerosis complex (TSC) who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. The effectiveness is based on demonstration of durable objective response, as evidenced by reduction in SEGA tumor volume. Improvement in diseaserelated symptoms and overall survival in patients with SEGA and TSC has not been demonstrated. (1.5)
DrugBank Targets:13 Serine/threonine-protein kinase mTOR
Mechanism of Action:15 
Target: mTOR
Action: inhibitor
FDA: Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of thePI3K/AKT pathway. The mTOR pathway is dysregulated in several human cancers. Everolimus binds to an intracellularprotein, FKBP-12, resulting in an inhibitory complex formation with mTOR complex 1 (mTORC1) and thus inhibition ofmTOR kinase activity. Everolimus reduced the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic initiationfactor 4E-binding protein (4E-BP1), downstream effectors of mTOR, involved in protein synthesis. S6K1 is a substrate ofmTORC1 and phosphorylates the activation domain 1 of the estrogen receptor which results in ligand-independentactivation of the receptor. In addition, everolimus inhibited the expression of hypoxia-inducible factor (e.g., HIF-1) andreduced the expression of vascular endothelial growth factor (VEGF). Inhibition of mTOR by everolimus has been shownto reduce cell proliferation, angiogenesis, and glucose uptake in in vitro and/or in vivo studies.Constitutive activation of the PI3K/Akt/mTOR pathway can contribute to endocrine resistance in breast cancer. In vitrostudies show that estrogen-dependent and HER2+ breast cancer cells are sensitive to the inhibitory effects of everolimus,and that combination treatment with everolimus and Akt, HER2, or aromatase inhibitors enhances the anti-tumor activityof everolimus in a synergistic manner.Two regulators of mTORC1 signaling are the oncogene suppressors tuberin-sclerosis complexes 1 and 2 (TSC1, TSC2).Loss or inactivation of either TSC1 or TSC2 leads to activation of downstream signaling. In TSC, a genetic disorder,inactivating mutations in either the TSC1 or the TSC2 gene lead to hamartoma formation throughout the body.

Drugs for Tuberous Sclerosis-1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 55)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Doxycyclineapproved, investigationalPhase 4219564-25-054671203, 5281011
Synonyms:
(2E,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(2Z)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(2Z,4S,4aR,5S,5aR,6R)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(2Z,4S,4aR,5S,5aR,6R,12aS)-2-[amino(hydroxy)methylidene]-4-(dimethylamino)-5,10,11,12a-tetrahydroxy-6-methyl-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(4S,4AR,5S,5ar,6R,12as)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
(4S,4aR,5S,5aR,6R,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
10597-92-9
17086-28-1 (mono-hydrate)
2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)
24390-14-5
41411-66-9 (6-epimer, mono-hydrochloride)
5-Hydroxy-alpha-6-deoxytetracycline
564-25-0
6-Deoxyoxytetracycline
6-Deoxytetracycline
6-alpha-Deoxy-5-oxytetracycline
6-alpha-deoxy-5-oxytetracycline
69935-17-7 (mono-hydrochloride, di-hydrate)
6alpha-Deoxy-5-oxytetracycline
6α-deoxy-5-oxytetracycline
7164-70-7
7264-10-0
94088-85-4 (calcium salt (1:2))
AB08 (*Fosfatex)
AC1NQXW7
AC1NS4CW
AC1NUYS8
AC1O8PYM
Adoxa
Alodox
Alti-Doxycycline
Apo-Doxy
Atridox
Azudoxat
BCBcMAP01_000024
BIDD:GT0146
BMY-28689
BPBio1_000951
BSPBio_000863
BSPBio_001936
BU-3839T
C06973
CHEBI:50845
CHEMBL1433
CID5281011
CID5353597
CID5463943
CID6713981
CPD001550033
D07876
DB00254
DMSC (*Fosfatex)
DOXCYCLINE ANHYDROUS
DOXY
DOXYCYCLINE CALCIUM
DOXYCYCLINE MONOHYDRATE
Deoxymykoin
DivK1c_000345
Doryx
Dossiciclina
Dossiciclina [DCIT]
Doxcycline anhydrous
Doxiciclina
Doxiciclina [INN-Spanish]
Doxiciclina [Italian]
Doxitard
Doxivetin
Doxy 100
Doxy-Caps
Doxy-Puren
Doxy-Tabs
Doxycen
Doxychel
Doxychel (TN)
Doxycin
Doxycyclin
Doxycycline
Doxycycline (200mg/day) or Placebo
Doxycycline (INN)
 
Doxycycline (TN)
Doxycycline (anhydrous)
Doxycycline (internal use)
Doxycycline Hyclate
Doxycycline Monohydrate
Doxycycline anhydrous
Doxycycline hyclate
Doxycycline hydrochloride
Doxycycline-Chinoin
Doxycyclinum
Doxycyclinum [INN-Latin]
Doxysol
Doxytec
Doxytetracycline
EINECS 209-271-1
GS-3065 (*monohydrate)
HMS2090E06
HSDB 3071
Hydramycin
IDI1_000345
Investin
Jenacyclin
KBio1_000345
KBio2_001287
KBio2_003855
KBio2_006423
KBio3_001156
KBioGR_001133
KBioSS_001287
LS-187766
LS-93868
Liviatin
Lopac0_000405
MolPort-002-507-423
Monodox
Monodox (*monohydrate)
Morgidox
NCGC00161602-01
NCGC00161602-03
NCGC00161602-04
NCGC00167961-01
NCGC00179395-01
NINDS_000345
NSC633557
Novo-Doxylin
Nu-Doxycycline
Ocudox
Oracea
Prestwick0_000852
Prestwick1_000852
Prestwick2_000852
Prestwick3_000852
Ronaxan
SAM002589932
SMP1_000107
SPBio_000246
SPBio_002784
STOCK1N-34341
Spanor
Spectrum2_000143
Spectrum3_000408
Spectrum4_000527
Spectrum5_000947
Spectrum_000807
Supracyclin
UNII-334895S862
UPCMLD-DP021
UPCMLD-DP021:001
Vibra-tabs
Vibramycin
Vibramycin (*monohydrate)
Vibramycin Monohydrate
Vibramycin Novum
Vibramycine
Vibravenos
Vivox (*Hyclate)
alpha-6-Deoxy-5-hydroxytetracycline
alpha-6-Deoxyoxytetracycline
alpha-Doxycycline
doxycycline
2
EverolimusapprovedPhase 4, Phase 3, Phase 2, Phase 11797159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
Afinitor Disperz
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
VOTUBIA
Zortress
everolimus
3
Miconazoleapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1302622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
Desenex
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Makesense
Micantin (nitrate)
Micatin
 
Miconasil Nitrate
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Oravig
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
Rash Relief Antifungal
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
4
Sirolimusapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1179753123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
5
VigabatrinapprovedPhase 41960643-86-95665
Synonyms:
( inverted question mark)-gamma-Vinyl GABA
(?)-gamma-Vinyl GABA
(R,S)-4-Amino-5-hexenoic acid
.gamma.-Vinyl-.gamma.-aminobutyric acid
.gamma.-Vinyl-GABA
4-Amino-5-hexenoic acid
4-Aminohexenoic acid
4-aminohex-5-enoic acid
60643-86-9
74046-07-4
AB00053309
AC1L1KUZ
Acid, gamma-Vinyl-gamma-Aminobutyric
Aventis Brand of Vigabatrin
BPBio1_000465
BPBio1_000925
BSPBio_000421
BSPBio_003469
Biomol-NT_000247
C07500
C6H11NO2
CHEBI:241484
CHEMBL89598
CID5665
CPP-109
D00535
D020888
DB01080
DivK1c_006760
EU-0101277
GVG
HMS1569F03
HMS2094M21
Hexenoic acid, 4-amino
Hoechst Brand of Vigabatrin
KBio1_001704
KBio2_000848
KBio2_003416
KBio2_005984
KBio3_002973
KBioSS_000848
LS-75569
Lopac0_001277
M071754
MDL 71,754
MDL 71754
 
MDL-71754
MolPort-003-666-796
NCGC00016087-03
NCGC00016087-08
NCGC00024802-02
NCGC00024802-03
NCGC00024802-04
NCGC00024802-05
NCGC00024802-06
Prestwick0_000501
Prestwick1_000501
Prestwick2_000501
Prestwick3_000501
Prestwick_837
RMI 71754
RMI-71754
RMI-71890
SPBio_002342
SPECTRUM1502036
Sabril
Sabril (TN)
Sabrilex
SpecPlus_000664
Spectrum3_001825
Spectrum_000368
V 8261
V8261_SIGMA
Vigabatrin
Vigabatrin (JAN/USAN/INN)
Vigabatrin Aventis Brand
Vigabatrin Hoechst Brand
Vigabatrin Yamanouchi Brand
Vigabatrin [USAN:BAN:INN]
Vigabatrin [USAN:INN:BAN]
Vigabatrina
Vigabatrina [Spanish]
Vigabatrine
Vigabatrine [French]
Vigabatrinum
Vigabatrinum [Latin]
Yamanouchi Brand of Vigabatrin
gamma Vinyl GABA
gamma Vinyl gamma Aminobutyric Acid
gamma-Vinyl GABA
gamma-Vinyl-GABA
gamma-Vinyl-gamma-Aminobutyric Acid
gamma-Vinyl-gamma-aminobutyric acid
vigabatrin
6Antibiotics, AntitubercularPhase 4, Phase 3, Phase 2, Phase 15971
7Antifungal AgentsPhase 4, Phase 3, Phase 2, Phase 13015
8Immunologic FactorsPhase 4, Phase 3, Phase 2, Phase 118483
9Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 110422
10AntimalarialsPhase 41058
11Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 19140
12Antiparasitic AgentsPhase 41854
13Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 117220
14Antiprotozoal AgentsPhase 41730
15Neurotransmitter AgentsPhase 4, Phase 214795
16AnticonvulsantsPhase 42249
17
Melatoninapproved, nutraceuticalPhase 3, Phase 123473-31-4896
Synonyms:
0E2B08C1-B325-45B1-8939-6F9081EFDFA4
4-ACETAMIDO-4'-ISOTHIO-CYANATOSTILBENE-2,2'-DISULFONIC ACID
5-22-12-00042 (Beilstein Handbook Reference)
5-Methoxy-N-acetyltryptamine
5-methoxy-N-acetyltryptamine
73-31-4
A4039/0172195
AB00053279
AC1L1A9Q
AC1Q4F1W
AC1Q4F1X
AKOS000276269
Acetamide, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)- (9CI)
Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]- (9CI)
Acetamide, N-[2-(5-methoxyindol-3-yl)ethyl]- (6CI,8CI)
Acetamide, {N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-}
Acetamide, {N-[2-(5-methoxyindol-3-yl)ethyl]-}
BAS 01281092
BIDD:ER0618
BPBio1_000590
BRD-K97530723-001-07-6
BRN 0205542
BSPBio_000536
BSPBio_003006
Bio-0635
C01598
CAS-73-31-4
CCRIS 3472
CHEBI:16796
CHEMBL45
CID896
ChemDiv2_003916
Circadin
D008550
D08170
DB01065
DB08189
DivK1c_000353
EINECS 200-797-7
EU-0100787
HMS1380B22
HMS1569K18
HMS1921E04
HMS2089F09
HMS501B15
HSCI1_000400
HSDB 7509
I05-0076
I10-0345
IDI1_000353
IDI1_002631
IN1244
KBio1_000353
KBio2_000665
KBio2_003233
KBio2_005801
KBio3_002226
KBioGR_000591
KBioSS_000665
L001261
LS-1623
Lopac-M-5250
Lopac0_000787
M 5250
M-1200
M-1250
M1105
M5250_SIGMA
ML1
MLS000859594
MLS001055382
MLS001240204
MT6
Mela-T
Melapure
Melatol
Melatonex
Melatonex, Melatonin
Melatonin
Melatonin (synth.) standard-grade
 
Melatonin (synth.) ultra-pure
Melatonina
Melatonina (TN)
Melatonine
Melovine
MolPort-000-737-883
N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide
N-(2-(5-Methoxyindol-3-yl)ethyl)-Acetamide
N-(2-(5-Methoxyindol-3-yl)ethyl)acetamide
N-Acetyl-5-methoxy-tryptamine
N-Acetyl-5-methoxy-tryptamine Melatonine
N-Acetyl-5-methoxytryptamine
N-[2-(5-Methoxy-1H-indol-3-yl)-ethyl]-acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]-Acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]acetamide
N-[2-(5-Methoxyindol-3-yl)ethyl]-Acetamide
N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide
N-[2-(5-methoxyindol-3-yl)ethyl]acetamide
N-acetyl-5-methoxy-tryptamine
NCGC00015680-01
NCGC00015680-02
NCGC00015680-03
NCGC00015680-06
NCGC00015680-13
NCGC00090727-01
NCGC00090727-02
NCGC00090727-03
NCGC00090727-04
NCGC00090727-05
NCGC00090727-06
NCGC00090727-07
NCGC00090727-08
NCGC00090727-09
NCI60_004378
NINDS_000353
NMR/14327425
NSC 113928
NSC113928
NSC56423
Nature'S Harmony
Night Rest
Oprea1_104553
Oprea1_814234
PREVENTION 1 (MELATONIN) (PREVENTION 1)
PREVENTION 2 (MELATONIN)
PREVENTION 3 (MELATONIN)
PREVENTION 4 (MELATONIN)
PREVENTION 5 (MELATONIN)
Pineal Hormone
Posidorm
Prestwick0_000458
Prestwick1_000458
Prestwick2_000458
Prestwick3_000458
Prestwick_312
Regulin
Revital Melatonin
Rx Balance
S1204_Selleck
SDCCGMLS-0065812.P001
SDCCGMLS-0065812.P002
SMP2_000309
SMR000326666
SPBio_001527
SPBio_002475
SPECTRUM1500690
STK386880
Sleep Right
Spectrum2_001344
Spectrum3_001393
Spectrum4_000066
Spectrum5_001745
Spectrum_000185
TNP00300
UNII-JL5DK93RCL
Vivitas
WLN: T56 BMJ D2MV1 GO1
ZINC00057060
{N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-} Acetamide
{N-[2-(5-methoxyindol-3-yl)ethyl]-} Acetamide
18AntioxidantsPhase 3, Phase 12442
19Protective AgentsPhase 3, Phase 15651
20Central Nervous System DepressantsPhase 3, Phase 110016
21Pharmaceutical SolutionsPhase 3, Phase 27004
22Phase 3
23StrawberryNutraceuticalPhase 375
24
SimvastatinapprovedPhase 1, Phase 249379902-63-954454
Synonyms:
(+)-Simvastatin
(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate
2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
79902-63-9
AC-1530
AC1L1H1F
AKOS005111006
ARONIS24119
BCBcMAP01_000007
BIDD:GT0769
BPBio1_001001
BRD-K22134346-001-05-8
BRN 4768037
BSPBio_000909
BSPBio_002337
Bio-0672
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,*aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
C25H38O5
CCRIS 7558
CHEBI:9150
CHEMBL1064
CID54454
CPD000718785
Cholestat
Coledis
Colemin
Corolin
D00434
D019821
DRG-0320
Denan
DivK1c_006991
Eucor
HMS1570N11
HMS1922H13
HMS2089D12
HMS2093E06
HSDB 7208
InChI=1/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1
KBio1_001935
KBio2_002197
KBio2_004765
KBio2_007333
KBio3_001557
KBioGR_001244
KBioSS_002197
KS-1113
Kolestevan
L 644128-000U
LS-46264
Labistatin
Lipex
Lipinorm
Liponorm
Lipovas
Lodales
MK 0733
MK 733
MK-0733
MK-733
MK733
MLS001304029
MLS001333077
MLS001333078
 
MLS002154038
Medipo
Modutrol
MolPort-002-507-345
MolPort-002-885-862
NCGC00017324-01
NCGC00017324-02
NCGC00017324-03
Nivelipol
Nor-Vastina
Pantok
Pepstatin
Prestwick0_000865
Prestwick1_000865
Prestwick2_000865
Prestwick3_000865
Prestwick_171
Rechol
Rendapid
S1792_Selleck
S6196_SIGMA
SAM002589969
SMR000718785
SPBio_001881
SPBio_002830
SPECTRUM1504236
STK801938
Simcor
Simovil
Simvast CR
Simvastatin
Simvastatin & Primycin
Simvastatin (JAN/USP/INN)
Simvastatin [USAN:INN:BAN]
Simvastatin [Usan:Ban:Inn]
Simvastatin lactone
Simvastatin, Compactin
Simvastatina
Simvastatina [Spanish]
Simvastatine
Simvastatine [French]
Simvastatinum
Simvastatinum [Latin]
Simvotin
Sinvacor
Sinvascor
Sivastin
SpecPlus_000895
Spectrum2_001671
Spectrum3_000669
Spectrum4_000632
Spectrum5_001428
Spectrum_001717
Statin
Synvinolin
TNP00259
UNII-AGG2FN16EV
Valemia
Vasotenal
Velostatin
Vytorin
ZINC03780893
Zocor
Zocor (TN)
Zocor, Simlup, Simcard, Simvacor, Simvoget, Zorced, Simvastatin
Zocord
[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate
butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 alpha,3 alpha,7 beta,8 beta(2S*,4S*),-8a beta
nchembio790-comp16
simvastatin
25
Letrozoleapproved, investigationalPhase 2358112809-51-53902
Synonyms:
1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole
1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole
112809-51-5
4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile
4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile)
4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile
4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-Benzonitrile Letrozole
4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile
4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile
4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile
AB00514009
AC-1193
AC1L1GYT
AKOS005145822
BIDD:GT0015
BIDD:PXR0130
BPBio1_001331
BRD-K88789588-001-03-2
BSPBio_001209
Bio-0057
C067431
C08163
C17H11N5
CAS-112809-51-5
CCRIS 8822
CGS 20267
CGS 20267, Femara, Piroxicam, Letrozole
CGS-20267
CHEBI:6413
CHEMBL1444
CID3902
CPD000466343
D00964
 
DB01006
FEM-345
Femara
Femara (TN)
Femera
HMS1571M11
HMS2051E08
HMS2089L22
HSDB 7461
I06-0022
LS-38788
Letoval
Letrozol
Letrozole
Letrozole (JAN/USP/INN)
Letrozole [USAN:INN]
MLS000759455
MLS001424038
MLS002584991
MolPort-003-848-373
NCGC00016973-01
NCGC00016973-02
NSC719345
Novartis Brand of Letrozole
Prestwick0_001025
Prestwick1_001025
Prestwick2_001025
Prestwick3_001025
S1235_Selleck
SAM001246649
SMR000466343
SPBio_003070
TL8000371
UNII-7LKK855W8I
ZINC03778874
letrozole
26
MetforminapprovedPhase 21645657-24-9, 1115-70-414219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMBG
DMGG
Diabefagos
Diabetosan
Diabex
Diaformin
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Meguan
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin Hydrochloride
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
Obimet
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
27
Octreotideapproved, investigationalPhase 219883150-76-9383414, 6400441
Synonyms:
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
79517-01-4 (acetate salt)
83150-76-9
AC1L1GVU
AC1L8LCD
AC1L9M4X
C07306
C5H12O2.C4H10
CHEBI:427278
CHEBI:611465
CHEMBL1680
CID383414
CID448601
CID54374
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide
D00442
DRG-0115
HMS2090C09
HS-2020
L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*
L000453
 
LS-177735
LS-187135
Longastatin
NCGC00181796-01
NCI60_025753
Ocphyl
Octreotida
Octreotida [Spanish]
Octreotide
Octreotide (USAN/INN)
Octreotide Acetate
Octreotide Acetate Salt
Octreotide [USAN:INN:BAN]
Octreotide acetate
Octreotide-LAR
Octreotidum
Octreotidum [Latin]
Octrotide
SAN 201-995
SM 201-995
SMS 201-995
SMS-201-995
Sandostatin
Sandostatine
Sandoz 201-995
UNII-RWM8CCW8GP
nchembio.184-comp3
zacycloicosane-4-carboxamide acetate
28
OlaparibapprovedPhase 2104763113-22-023725625
Synonyms:
4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one
4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one
4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
763113-22-0
937799-91-2
AKOS005145764
AZD 2281
AZD-2281
AZD2281
 
Acylpiperazine analogue, 47
CHEMBL521686
EC-000.2324
EN002690
FT-0083489
KU-0059436
KU-59436
Olaparib
Olaparib, KU-0059436, AZD2281, KU0059436, AZD2281
S1060_Selleck
olaparib
29
Sorafenibapproved, investigationalPhase 2671284461-73-0216239, 406563
Synonyms:
284461-73-0
4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide
4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE
AB1004622
AC-1674
AC1L50CF
BAX
BAY 43-9006
BAY 43-9006 (free base)
BAY 43-9006 tosylate salt
BAY 439006
BAY 54-9085 (tosylate salt)
BAY-43-0006
BAY-43-9006
BAY-54-9085
BAY43-9006
BRD-K23984367-001-01-8
Bio-0100
CHEBI:47228
CHEBI:50924
CHEMBL1336
CID216239
 
D08524
DB00398
DB07438
EN002709
I06-0856
K00597a
Kinome_766
LS-186067
LS-187021
LS-187788
MolPort-003-850-270
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea
N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
NCGC00167488-01
NSC-724772
NSC747971
Nexavar
STK627350
Sorafenib
Sorafenib (INN)
Sorafenib Tosylate
Sorafenib [INN]
Sorafenib tosylate
Sorafenibum
UNII-9ZOQ3TZI87
ZINC01493878
nchembio.117-comp17
sorafenib
sorafenibum
30
Propranololapproved, investigationalPhase 2202525-66-64946
Synonyms:
(+-)-Propranolol
(1)-1-(Isopropylamino)-3-(naphthyloxy)propan-2-ol
(R)-(+)-propranolol
(S)-(-)-PROPRANOLOL
1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol
1-(1-Naphthyloxy)-2-hydroxy-3-(isopropylamino)propane
1-(Isopropylamino)-3-(1-naphthoxy)-propan-2-ol
1-(Isopropylamino)-3-(1-naphthyloxy)-2-propanol
1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol
1-(naphthalen-1-yloxy)-3-(propan-2-ylamino)propan-2-ol
1-Isopropylamino-3-(1-naphthyloxy)-2-propanol
1-[(1-methylethyl)amino]-3-(naphthalen-1-yloxy)propan-2-ol
1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol
13013-17-7
2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)- (9CI)
2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, (+-)- (9CI)
3-(naphthalen-1-yloxy)-1-(propan-2-ylamino)propan-2-ol
4199-09-1
4199-10-4
525-66-6
AB00053537
AC1L1JA4
AC1Q1QBV
AC1Q1QC0
AKOS000588816
AY 64043
AY-20694
Anaprilin
Anapriline
Angilol
Apsolol
Avlocardyl
BPBio1_001040
BRD-A10070317-003-06-9
BSPBio_000944
BSPBio_002682
Bedranol
Beprane
Berkolol
Beta Neg
Beta-Neg
Beta-Propranolol
Beta-Tablinen
Beta-Timelets
Betachron
Betadren
Betalong
Bio-0732
Bio1_000367
Bio1_000856
Bio1_001345
C07407
C16H21NO2
CBDivE_006180
CCRIS 3082
CHEBI:8499
CHEMBL27
CID4946
Cardinol
Caridolol
Corpendol
D,L-Propranolol
D08443
DB00571
DL-Propranolol hydrochloride
Deralin
DivK1c_000023
Dl-Propranolol Hydrochloride
Dociton
Duranol
EINECS 208-378-0
EINECS 235-867-6
Efektolol
Elbrol
Etalong
Euprovasin
Frekven
HMS2090L21
Hemangeol
Herzbase
ICI 45520
IDI1_000023
INDERIDE-40/25
INDERIDE-80/25
Ikopal
Inderal
Inderal LA
Inderal La
Inderal hydrochloride
Inderalici
Inderex
Inderide
Inderol
Indobloc
 
Innopran XL
Innopran Xl
Intermigran
KBio1_000023
KBio2_002515
KBio2_005083
KBio2_007651
KBio3_001766
KBio3_001902
KBio3_002993
KBioGR_001347
KBioGR_001684
KBioGR_002515
KBioSS_002523
Kemi
Kemi S
L000679
LS-122410
LS-184129
Lopac0_000896
Migrastat
MolPort-001-794-623
NCGC00015798-07
NCGC00024690-02
NCGC00024690-03
NINDS_000023
NSC91523
Naprilin
Obsidan
Obzidan
Oposim
Oprea1_304193
PDSP1_000767
PDSP1_001607
PDSP1_001608
PDSP2_000755
PDSP2_001591
PDSP2_001592
Prano-Puren
Pranolol
Prestwick0_000952
Prestwick1_000952
Prestwick2_000952
Prestwick3_000952
Pronovan
Propanalol
Propanix
Propanolol
Propanolol [INN-Spanish]
Prophylux
Propranalol
Propranolol
Propranolol (INN)
Propranolol (TN)
Propranolol Hcl
Propranolol Hcl Intensol
Propranolol Hydrochloride
Propranolol [INN:BAN]
Propranololo
Propranololo [DCIT]
Propranololum
Propranololum [INN-Latin]
Propranur
Proprasylyt
Pylapron
R,S-Propranolol Hydrochloride
Racemic propranolol
Rapynogen
Reducor
Reducor Line
Reducor line
SPBio_001361
SPBio_001658
SPBio_003093
STK735510
Sagittol
Sawatal
Servanolol
Sloprolol
Spectrum2_001301
Spectrum2_001699
Spectrum3_000883
Spectrum3_001071
Spectrum4_000974
Spectrum4_001222
Spectrum5_000751
Sumial
Tesnol
UNII-9Y8NXQ24VQ
b-Propranolol
beta-Propranolol
cMAP_000071
etalong
propranolol
propranololo
β-Propranolol
31
Lapatinibapproved, investigational, Approved March 2007Phase 2294231277-92-2, 388082-78-8208908, 9941095
Synonyms:
1xkk
231277-92-2
388082-78-8
4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline
AB1004631
AC-1314
AC1L4LL4
AKOS005145766
CHEBI:49603
CHEMBL1201179
CHEMBL554
CID11557040
CID208908
D04024
D08108
DB01259
DB02584
EN002712
FMM
GSK 572016
GSK572016
GW 572016
GW 572016X
GW-2016
GW-572016
GW-572016F
GW2016
GW572016
HMS2089H10
I01-1247
 
Kinome_3684
Kinome_3685
LAPATINIB DITOSYLATE MONOHYDRATE
LS-187029
LS-187771
Lapatinib
Lapatinib (INN)
Lapatinib Ditosylate
Lapatinib [INN]
Lapatinib ditosylate
Lapatinib ditosylate (USAN)
Lapatinib tosilate hydrate
Lapatinib tosilate hydrate (JAN)
Lapatinib, Tykerb, GW572016
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine
N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine
N-(3-chloro-4-((3-Fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine
N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
NCGC00167507-01
NSC745750
TL80090051
Tycerb
Tykerb
Tykerb (TN)
Tyverb
UNII-0VUA21238F
lapatinib
lapatinib ditosylate
nchembio866-comp20
32Angiogenesis InhibitorsPhase 23688
33Hydroxymethylglutaryl-CoA Reductase InhibitorsPhase 1, Phase 21804
34Gastrointestinal AgentsPhase 26401
35Adrenergic beta-AntagonistsPhase 2979
36Poly(ADP-ribose) Polymerase InhibitorsPhase 2250
37Adrenergic AgentsPhase 24204
38Protein Kinase InhibitorsPhase 23162
39Antineoplastic Agents, HormonalPhase 24256
40Adrenergic AntagonistsPhase 21253
41Hypoglycemic AgentsPhase 24503
42Anticholesteremic AgentsPhase 1, Phase 21732
43AntimetabolitesPhase 1, Phase 29454
44Hypolipidemic AgentsPhase 1, Phase 22228
45Estrogen AntagonistsPhase 21155
46Aromatase InhibitorsPhase 2721
47Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 29988
48HormonesPhase 211748
49Hormone AntagonistsPhase 210002
50EstrogensPhase 22144

Interventional clinical trials:

(show top 50)    (show all 55)
idNameStatusNCT IDPhase
1Rapamycin In Angiomyolipomas In Patients With Tuberous SclerosisCompletedNCT01217125Phase 4
2Doxycycline In Lymphangioleiomyomatosis (LAM)CompletedNCT00989742Phase 4
3Sabril for Complex Partial Seizures in Adult Tolerability Study (TS) PatientsRecruitingNCT01266291Phase 4
4Long-term Follow-up for Growth and Development of Pediatric Patients From CRAD001M2301Active, not recruitingNCT02338609Phase 4
5Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)CompletedNCT00789828Phase 3
6Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)CompletedNCT00790400Phase 3
7Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis ComplexRecruitingNCT01730209Phase 2, Phase 3
8A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex.RecruitingNCT02544763Phase 3
9Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment DisabilitiesRecruitingNCT01906866Phase 3
10A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset SeizuresActive, not recruitingNCT01713946Phase 3
11An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex.Enrolling by invitationNCT02544750Phase 3
12Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis ComplexNot yet recruitingNCT02634931Phase 3
13Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC)Not yet recruitingNCT02635789Phase 3
14Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAMCompletedNCT00457808Phase 2
15Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)CompletedNCT01289912Phase 2
16Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis ComplexCompletedNCT00411619Phase 1, Phase 2
17Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)CompletedNCT01070316Phase 1, Phase 2
18Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)CompletedNCT00792766Phase 1, Phase 2
19RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAMCompletedNCT00457964Phase 1, Phase 2
20Topical Rapamycin to Erase Angiofibromas in TSCCompletedNCT01526356Phase 2
21Everolimus for Cancer With TSC1 or TSC2 MutationRecruitingNCT02201212Phase 2
22A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous SclerosisRecruitingNCT01954693Phase 2
23Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockersRecruitingNCT02104011Phase 2
24Safety of Simvastatin in LAM and TSCRecruitingNCT02061397Phase 1, Phase 2
25A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCDRecruitingNCT02451696Phase 2
26Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 MutationsRecruitingNCT02352844Phase 2
27Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial CancerRecruitingNCT02188550Phase 2
28Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETsRecruitingNCT02294006Phase 2
29OLAParib COmbinationsRecruitingNCT02576444Phase 2
30Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: My Own Specific TreatmentRecruitingNCT02029001Phase 2
31Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAMActive, not recruitingNCT00490789Phase 2
32Rapalogues for Autism Phenotype in TSC: A Feasibility StudyActive, not recruitingNCT01929642Phase 2
33Sirolimus in Treating Patients With Angiomyolipoma of the KidneyActive, not recruitingNCT00126672Phase 2
34A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComaWithdrawnNCT01690871Phase 2
35Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)CompletedNCT01031901Phase 1
36Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep DisturbancesCompletedNCT01903681Phase 1
37Tuberous Sclerosis Complex: Facial Angiofibroma Skin CreamRecruitingNCT01853423Phase 1
38A Phase I Study of BKM120 and Everolimus in Advanced Solid MalignanciesRecruitingNCT01470209Phase 1
39Effect of Fasting on the Size of Abdominal Lymphatic Tumors in WomenCompletedNCT00552955
40Official Record of Patients Diagnosed With Lymphangioleiomyomatosis (LAM)CompletedNCT00001869
41Early Biomarkers of Autism in Infants With Tuberous Sclerosis Complex (TSC)RecruitingNCT01780441
42Genetic Heterogeneity and Genotype-phenotype Correlation of Children and Adults With Tuberous Sclerosis ComplexRecruitingNCT02654340
43Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)RecruitingNCT02461459
44Study of Skin Tumors in Tuberous SclerosisRecruitingNCT00001975
45Tuberous Sclerosis Complex Natural History Study: Renal ManifestationsRecruitingNCT00598455
46Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis ComplexRecruitingNCT02098759
47Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis ComplexRecruitingNCT02687633
48The Cognitive Variability in NF1 and TSC Monozygotic TwinsRecruitingNCT02436746
49Study of the Disease Process of LymphangioleiomyomatosisRecruitingNCT00001465
50Role of Genetic Factors in the Development of Lung DiseaseRecruitingNCT00001532

Search NIH Clinical Center for Tuberous Sclerosis-1

Genetic Tests for Tuberous Sclerosis-1

About this section

Genetic tests related to Tuberous Sclerosis-1:

id Genetic test Affiliating Genes
1 Tuberous Sclerosis Complex22 TSC2
2 Tuberous Sclerosis 122 TSC1

Anatomical Context for Tuberous Sclerosis-1

About this section

MalaCards organs/tissues related to Tuberous Sclerosis-1:

33
Skin, Kidney, Brain, Heart, Lung, Breast, Liver

Animal Models for Tuberous Sclerosis-1 or affiliated genes

About this section

Publications for Tuberous Sclerosis-1

About this section

Articles related to Tuberous Sclerosis-1:

idTitleAuthorsYear
1
Meta-analysis of cytochrome P4501A1 MspI gene polymorphism and childhood acute leukemia. (22365406)
2011

Variations for Tuberous Sclerosis-1

About this section

UniProtKB/Swiss-Prot genetic disease variations for Tuberous Sclerosis-1:

67
id Symbol AA change Variation ID SNP ID
1TSC1p.Leu191HisVAR_009399
2TSC1p.Met224ArgVAR_009401
3TSC1p.Gln654GluVAR_009407rs75820036
4TSC1p.Ala726GluVAR_009408
5TSC1p.Thr899SerVAR_009412
6TSC1p.Leu72ProVAR_054387
7TSC1p.Arg500GlnVAR_054391
8TSC1p.Leu117ProVAR_070637
9TSC1p.Leu180ProVAR_070643

Clinvar genetic disease variations for Tuberous Sclerosis-1:

5 (show all 109)
id Gene Variation Type Significance SNP ID Assembly Location
1TSC2NM_000548.4(TSC2): c.4642delC (p.Leu1548Cysfs)deletionPathogenicrs137854083GRCh37Chr 16, 2135303: 2135303
2TSC2NM_000548.4(TSC2): c.5024C> T (p.Pro1675Leu)single nucleotide variantPathogenicrs45483392GRCh37Chr 16, 2137898: 2137898
3TSC2NM_000548.4(TSC2): c.34A> T (p.Lys12Ter)single nucleotide variantPathogenicrs45512692GRCh37Chr 16, 2098650: 2098650
4TSC2NM_000548.4(TSC2): c.2056_2059dupTACT (p.Ser687Leufs)duplicationPathogenicrs137854337GRCh37Chr 16, 2121894: 2121897
5TSC2NM_000548.4(TSC2): c.1513C> T (p.Arg505Ter)single nucleotide variantPathogenicrs45517179GRCh37Chr 16, 2114342: 2114342
6TSC2NM_000548.4(TSC2): c.1832G> A (p.Arg611Gln)single nucleotide variantPathogenicrs28934872GRCh37Chr 16, 2120572: 2120572
7TSC2NM_000548.4(TSC2): c.2150T> G (p.Leu717Arg)single nucleotide variantPathogenicrs45517214GRCh37Chr 16, 2122294: 2122294
8TSC2NM_000548.4(TSC2): c.1432C> T (p.Gln478Ter)single nucleotide variantPathogenicrs121964862GRCh37Chr 16, 2113043: 2113043
9TSC2NM_000548.4(TSC2): c.1096G> T (p.Glu366Ter)single nucleotide variantPathogenicrs45517148GRCh37Chr 16, 2110791: 2110791
10TSC2NM_000548.4(TSC2): c.4508A> C (p.Gln1503Pro)single nucleotide variantPathogenicrs45516293GRCh37Chr 16, 2134966: 2134966
11TSC2NM_000548.4(TSC2): c.5238_5255del18 (p.His1746_Arg1751del)deletionPathogenicrs137854218GRCh37Chr 16, 2138305: 2138322
12TSC2NM_000548.4(TSC2): c.2714G> A (p.Arg905Gln)single nucleotide variantPathogenicrs45517259GRCh37Chr 16, 2126143: 2126143
13TSC2NM_000548.4(TSC2): c.2713C> T (p.Arg905Trp)single nucleotide variantPathogenicrs45517258GRCh37Chr 16, 2126142: 2126142
14TSC2NM_000548.4(TSC2): c.2713C> G (p.Arg905Gly)single nucleotide variantPathogenicrs45517258GRCh37Chr 16, 2126142: 2126142
15TSC2NM_000548.4(TSC2): c.2355+2_2355+5delTAGGdeletionPathogenicrs137854250GRCh37Chr 16, 2122986: 2122989
16TSC2NM_000548.4(TSC2): c.1322G> A (p.Trp441Ter)single nucleotide variantPathogenicrs45515894GRCh37Chr 16, 2112562: 2112562
17TSC1NM_000368.4(TSC1): c.2515_2518delGAGT (p.Glu839Argfs)deletionPathogenicrs794727320GRCh37Chr 9, 135776209: 135776212
18TSC1NM_000368.4(TSC1): c.2675_2676delGA (p.Arg892Lysfs)deletionPathogenicrs118203726GRCh38Chr 9, 132897560: 132897561
19TSC1NM_000368.4(TSC1): c.1152delA (p.Gly385Glufs)deletionPathogenicrs118203501GRCh37Chr 9, 135786069: 135786069
20TSC1NM_000368.4(TSC1): c.1257delC (p.Arg420Glyfs)deletionPathogenicrs118203506GRCh37Chr 9, 135785964: 135785964
21TSC1NM_000368.4(TSC1): c.1431_1434delAGAA (p.Glu478Lysfs)deletionPathogenicrs118203527GRCh37Chr 9, 135782122: 135782125
22TSC1NM_000368.4(TSC1): c.1525C> T (p.Arg509Ter)single nucleotide variantPathogenicrs118203542GRCh37Chr 9, 135781440: 135781440
23TSC1NM_000368.4(TSC1): c.1580_1581delAG (p.Gln527Argfs)deletionPathogenicrs118203550GRCh37Chr 9, 135781384: 135781385
24TSC1NM_000368.4(TSC1): c.1959dupA (p.Gln654Thrfs)duplicationPathogenicrs118203603GRCh37Chr 9, 135781006: 135781006
25TSC1NM_000368.4(TSC1): c.1963C> T (p.Gln655Ter)single nucleotide variantPathogenicrs118203606GRCh37Chr 9, 135781002: 135781002
26TSC1NM_000368.4(TSC1): c.1997+1G> Asingle nucleotide variantPathogenicrs118203610GRCh37Chr 9, 135780967: 135780967
27TSC1NM_000368.4(TSC1): c.2074C> T (p.Arg692Ter)single nucleotide variantPathogenicrs118203631GRCh37Chr 9, 135779172: 135779172
28TSC1NM_000368.4(TSC1): c.211-2A> Csingle nucleotide variantPathogenicrs118203352GRCh37Chr 9, 135801128: 135801128
29TSC1NM_000368.4(TSC1): c.2356C> T (p.Arg786Ter)single nucleotide variantPathogenicrs118203682GRCh37Chr 9, 135778027: 135778027
30TSC1NM_000368.4(TSC1): c.2509_2512delAACA (p.Asn837Valfs)deletionPathogenicrs118203707GRCh37Chr 9, 135776215: 135776218
31TSC1NM_000368.4(TSC1): c.2569delG (p.Glu857Argfs)deletionPathogenicrs118203712GRCh37Chr 9, 135776158: 135776158
32TSC1NM_000368.4(TSC1): c.271_272delTC (p.Ser91Valfs)deletionPathogenicrs118203360GRCh37Chr 9, 135801065: 135801066
33TSC1NM_000368.4(TSC1): c.491G> A (p.Trp164Ter)single nucleotide variantPathogenicrs118203387GRCh37Chr 9, 135798752: 135798752
34TSC1NM_000368.4(TSC1): c.664-1G> Csingle nucleotide variantPathogenicrs118203423GRCh37Chr 9, 135796824: 135796824
35TSC1NM_000368.4(TSC1): c.682C> T (p.Arg228Ter)single nucleotide variantPathogenicrs118203427GRCh37Chr 9, 135796805: 135796805
36TSC1NM_000368.4(TSC1): c.733C> T (p.Arg245Ter)single nucleotide variantPathogenicrs118203434GRCh37Chr 9, 135796754: 135796754
37TSC1NM_000368.4(TSC1): c.737+1G> Asingle nucleotide variantPathogenicrs118203438GRCh37Chr 9, 135796749: 135796749
38TSC1NM_000368.4(TSC1): c.812_813delAT (p.Tyr271Terfs)deletionPathogenicrs118203451GRCh37Chr 9, 135787769: 135787770
39TSC1NM_000368.4(TSC1): c.901_902delCA (p.Gln301Glufs)deletionPathogenicrs118203464GRCh37Chr 9, 135787680: 135787681
40TSC1NM_000368.4(TSC1): c.973C> T (p.Gln325Ter)single nucleotide variantPathogenicrs118203474GRCh37Chr 9, 135786896: 135786896
41TSC1NM_000368.4(TSC1): c.989_990delTG (p.Leu330Glnfs)deletionPathogenicrs118203479GRCh37Chr 9, 135786879: 135786880
42TSC1NM_000368.4(TSC1): c.989dupT (p.Ser331Glufs)duplicationPathogenicrs118203478GRCh37Chr 9, 135786880: 135786880
43TSC2NM_000548.4(TSC2): c.1372C> T (p.Arg458Ter)single nucleotide variantPathogenicrs45517169GRCh37Chr 16, 2112983: 2112983
44TSC2NM_000548.4(TSC2): c.226-2A> Gsingle nucleotide variantPathogenicrs45517096GRCh37Chr 16, 2103341: 2103341
45TSC2NM_000548.4(TSC2): c.2356-2A> Csingle nucleotide variantPathogenicrs45517229GRCh37Chr 16, 2124199: 2124199
46TSC2NM_000548.4(TSC2): c.3095G> C (p.Arg1032Pro)single nucleotide variantLikely pathogenicrs45491698GRCh37Chr 16, 2129161: 2129161
47TSC2NM_000548.4(TSC2): c.3206_3207delTG (p.Val1069Aspfs)deletionPathogenicrs137854076GRCh37Chr 16, 2129351: 2129352
48TSC2NM_000548.4(TSC2): c.3412C> T (p.Arg1138Ter)single nucleotide variantPathogenicrs45451497GRCh37Chr 16, 2130180: 2130180
49TSC2NM_000548.4(TSC2): c.352dupG (p.Val118Glyfs)duplicationPathogenicrs137853982GRCh37Chr 16, 2104312: 2104312
50TSC2NM_000548.4(TSC2): c.4115_4116delTG (p.Val1372Glyfs)deletionPathogenicrs137854368GRCh37Chr 16, 2134338: 2134339
51TSC2NM_000548.4(TSC2): c.4544_4547delACAA (p.Asn1515Serfs)deletionPathogenicrs137854175GRCh37Chr 16, 2135002: 2135005
52TSC2NM_000548.4(TSC2): c.4573C> T (p.Gln1525Ter)single nucleotide variantPathogenicrs45517352GRCh37Chr 16, 2135234: 2135234
53TSC2NM_000548.4(TSC2): c.4842_4844delCAT (p.Ile1614del)deletionPathogenicrs137854331GRCh37Chr 16, 2136373: 2136375
54TSC2NM_000548.4(TSC2): c.5150T> C (p.Leu1717Pro)single nucleotide variantPathogenicrs45517398GRCh37Chr 16, 2138130: 2138130
55TSC2NM_000548.4(TSC2): c.5252_5259+19del27deletionPathogenicrs137854397GRCh37Chr 16, 2138319: 2138345
56TSC2NM_000548.4(TSC2): c.646G> T (p.Glu216Ter)single nucleotide variantPathogenicrs45517118GRCh37Chr 16, 2106243: 2106243
57TSC2NM_000548.4(TSC2): c.976-15G> Asingle nucleotide variantPathogenicrs45517150GRCh37Chr 16, 2110656: 2110656
58TSC2NM_000548.4(TSC2): c.648+1G> Asingle nucleotide variantPathogenicrs45488893GRCh37Chr 16, 2106246: 2106246
59TSC2NM_000548.4(TSC2): c.5259+1delGdeletionPathogenicrs137854317GRCh37Chr 16, 2138327: 2138327
60TSC2NM_000548.4(TSC2): c.5160+1G> Asingle nucleotide variantPathogenicrs45517399GRCh37Chr 16, 2138141: 2138141
61TSC2NM_000548.4(TSC2): c.826_827delAT (p.Met276Valfs)deletionPathogenicrs137853977GRCh37Chr 16, 2107157: 2107158
62TSC2NM_000548.4(TSC2): c.4989+1G> Asingle nucleotide variantPathogenicrs45517386GRCh37Chr 16, 2136873: 2136873
63TSC2NM_000548.4(TSC2): c.5227C> T (p.Arg1743Trp)single nucleotide variantPathogenicrs45517412GRCh37Chr 16, 2138294: 2138294
64TSC2NM_000548.4(TSC2): c.4318C> T (p.Gln1440Ter)single nucleotide variantPathogenicrs45517337GRCh37Chr 16, 2134541: 2134541
65TSC2NM_000548.4(TSC2): c.3696dupT (p.Asn1233Terfs)duplicationPathogenicrs137854210GRCh37Chr 16, 2131681: 2131681
66TSC2NM_000548.4(TSC2): c.4096G> T (p.Glu1366Ter)single nucleotide variantPathogenicrs45517327GRCh37Chr 16, 2134319: 2134319
67TSC2NM_000548.4(TSC2): c.2666C> T (p.Ala889Val)single nucleotide variantPathogenicrs137854155GRCh37Chr 16, 2126095: 2126095
68TSC2NM_000548.4(TSC2): c.2459_2461delTCA (p.Ile820del)deletionLikely pathogenicrs137854128GRCh37Chr 16, 2124304: 2124306
69TSC2NM_000548.4(TSC2): c.1444-2A> Gsingle nucleotide variantPathogenicrs45517174GRCh37Chr 16, 2114271: 2114271
70TSC2NM_000548.4(TSC2): c.1831C> T (p.Arg611Trp)single nucleotide variantPathogenicrs45469298GRCh37Chr 16, 2120571: 2120571
71TSC2NM_000548.4(TSC2): c.1599+1G> Asingle nucleotide variantPathogenicrs45517182GRCh37Chr 16, 2114429: 2114429
72TSC2NM_000548.4(TSC2): c.1229T> G (p.Leu410Arg)single nucleotide variantLikely pathogenicrs137854298GRCh37Chr 16, 2111981: 2111981
73TSC2NM_000548.4(TSC2): c.2071delC (p.Arg691Alafs)deletionPathogenicrs137854071GRCh37Chr 16, 2121909: 2121909
74TSC2NM_000548.4(TSC2): c.2410T> C (p.Cys804Arg)single nucleotide variantLikely pathogenic, Pathogenicrs137853995GRCh37Chr 16, 2124255: 2124255
75TSC2NM_000548.4(TSC2): c.2108G> A (p.Trp703Ter)single nucleotide variantPathogenicrs45517213GRCh37Chr 16, 2122252: 2122252
76TSC2NM_000548.4(TSC2): c.3598C> T (p.Arg1200Trp)single nucleotide variantPathogenicrs45438205GRCh37Chr 16, 2130366: 2130366
77TSC2NM_000548.4(TSC2): c.2546-2A> Gsingle nucleotide variantPathogenicrs45517246GRCh37Chr 16, 2125798: 2125798
78TSC2NM_000548.4(TSC2): c.2639+1G> Csingle nucleotide variantPathogenicrs45517252GRCh37Chr 16, 2125894: 2125894
79TSC2NM_000548.4(TSC2): c.4912_4914delAAG (p.Lys1638del)deletionPathogenicrs137854261GRCh37Chr 16, 2136795: 2136797
80TSC2NM_000548.4(TSC2): c.848+1G> Asingle nucleotide variantPathogenicrs45466296GRCh37Chr 16, 2107180: 2107180
81TSC2NM_000548.4(TSC2): c.5138G> A (p.Arg1713His)single nucleotide variantPathogenicrs45517395GRCh37Chr 16, 2138118: 2138118
82TSC2NM_000548.4(TSC2): c.5138G> C (p.Arg1713Pro)single nucleotide variantLikely pathogenicrs45517395GRCh37Chr 16, 2138118: 2138118
83TSC2NM_000548.4(TSC2): c.5170C> T (p.Gln1724Ter)single nucleotide variantPathogenicrs45472701GRCh37Chr 16, 2138237: 2138237
84TSC2NM_000548.4(TSC2): c.5228G> A (p.Arg1743Gln)single nucleotide variantPathogenicrs45507199GRCh37Chr 16, 2138295: 2138295
85TSC2NM_000548.4(TSC2): c.4934_4935delTT (p.Phe1645Cysfs)deletionPathogenicrs137854249GRCh37Chr 16, 2136817: 2136818
86TSC2NM_000548.4(TSC2): c.4375C> T (p.Arg1459Ter)single nucleotide variantPathogenicrs45517340GRCh37Chr 16, 2134598: 2134598
87TSC2NM_000548.4(TSC2): c.569dupA (p.Tyr190Terfs)duplicationPathogenicrs137854359GRCh37Chr 16, 2105490: 2105490
88TSC2NM_000548.4(TSC2): c.3106T> C (p.Ser1036Pro)single nucleotide variantPathogenicrs45517281GRCh37Chr 16, 2129172: 2129172
89TSC2NM_000548.4(TSC2): c.4180_4181delCT (p.Leu1394Alafs)deletionPathogenicrs137854363GRCh37Chr 16, 2134403: 2134404
90TSC2NM_000548.4(TSC2): c.3397+5G> Asingle nucleotide variantPathogenicrs45501492GRCh37Chr 16, 2129675: 2129675
91TSC2NM_000548.4(TSC2): c.3401delG (p.Gly1134Alafs)deletionPathogenicrs137854314GRCh37Chr 16, 2130169: 2130169
92TSC2NM_000548.4(TSC2): c.4762C> T (p.Gln1588Ter)single nucleotide variantPathogenicrs45479192GRCh37Chr 16, 2136293: 2136293
93TSC2NM_000548.4(TSC2): c.2251C> T (p.Arg751Ter)single nucleotide variantPathogenicrs45517222GRCh37Chr 16, 2122880: 2122880
94TSC2NM_000548.4(TSC2): c.3611G> A (p.Gly1204Glu)single nucleotide variantLikely pathogenicrs45462194GRCh37Chr 16, 2131596: 2131596
95TSC2NM_000548.4(TSC2): c.1255C> T (p.Pro419Ser)single nucleotide variantPathogenicrs45517159GRCh37Chr 16, 2112007: 2112007
96TSC1NM_000368.4(TSC1): c.1888_1891delAAAG (p.Lys630Glnfs)deletionPathogenicrs118203595GRCh37Chr 9, 135781074: 135781077
97TSC1NM_000368.4(TSC1): c.749T> A (p.Leu250Ter)single nucleotide variantPathogenicrs118203447GRCh37Chr 9, 135787833: 135787833
98TSC1NM_000368.4(TSC1): c.1904_1905delCA (p.Thr635Argfs)deletionPathogenicrs118203597GRCh37Chr 9, 135781060: 135781061
99TSC1NM_000368.4(TSC1): c.671T> G (p.Met224Arg)single nucleotide variantPathogenicrs118203426GRCh37Chr 9, 135796816: 135796816
100TSC1NM_000368.4(TSC1): c.539T> C (p.Leu180Pro)single nucleotide variantPathogenicrs118203396GRCh37Chr 9, 135797330: 135797330
101TSC1NM_000368.4(TSC1): c.1680_1702del23 (p.Ser561Argfs)deletionPathogenicrs118203557GRCh37Chr 9, 135781263: 135781285
102TSC1NM_000368.4(TSC1): c.2041+1G> Asingle nucleotide variantPathogenicrs397514842GRCh37Chr 9, 135779797: 135779797
103TSC1NM_000368.4(TSC1): c.866C> G (p.Ser289Ter)single nucleotide variantPathogenicrs397514867GRCh37Chr 9, 135787716: 135787716
104TSC1NM_000368.4(TSC1): c.2698C> T (p.Gln900Ter)single nucleotide variantPathogenicrs397514871GRCh37Chr 9, 135772925: 135772925
105TSC1NM_000368.4(TSC1): c.2672delA (p.Asn891Thrfs)deletionPathogenicrs397514875GRCh37Chr 9, 135772951: 135772951
106TSC2NM_000548.4(TSC2): c.1447G> T (p.Glu483Ter)single nucleotide variantPathogenicrs397515297GRCh37Chr 16, 2114276: 2114276
107TSC2NM_000548.4(TSC2): c.4147_4163dup17 (p.Pro1389Alafs)duplicationPathogenicrs397515009GRCh37Chr 16, 2134370: 2134386
108TSC2NM_000548.4(TSC2): c.3236C> A (p.Ser1079Ter)single nucleotide variantPathogenicrs397515087GRCh37Chr 16, 2129381: 2129381
109TSC2NM_000548.4(TSC2): c.1959_1960delAG (p.Gly654Leufs)deletionPathogenicrs397515226GRCh37Chr 16, 2121797: 2121798

Expression for genes affiliated with Tuberous Sclerosis-1

About this section
Search GEO for disease gene expression data for Tuberous Sclerosis-1.

Pathways for genes affiliated with Tuberous Sclerosis-1

About this section

Pathways related to Tuberous Sclerosis-1 according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
9.5
2
Show member pathways
9.5TSC1, TSC2
39.5TSC1, TSC2
49.5TSC1, TSC2
59.5TSC1, TSC2
69.5TSC1, TSC2

GO Terms for genes affiliated with Tuberous Sclerosis-1

About this section

Biological processes related to Tuberous Sclerosis-1 according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1negative regulation of insulin receptor signaling pathwayGO:00466279.9TSC1, TSC2
2neural tube closureGO:00018439.8TSC1, TSC2
3regulation of cell cycleGO:00517269.5TSC1, TSC2
4negative regulation of cell proliferationGO:00082859.2TSC1, TSC2

Sources for Tuberous Sclerosis-1

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet